Stockscreener 앱 받기
23.60
5.98%
-1.50
시간 외 거래:
23.52
-0.08
-0.34%
전일 마감가:
$25.10
열려 있는:
$24.97
하루 거래량:
1.42M
Relative Volume:
0.91
시가총액:
$4.80B
수익:
-
순이익/손실:
$-464.20M
주가수익비율:
-8.7984
EPS:
-2.6823
순현금흐름:
$-423.09M
1주 성능:
-7.67%
1개월 성능:
-11.44%
6개월 성능:
+53.25%
1년 성능:
+25.60%
1일 변동 폭
$23.52
$25.41
1주일 범위
$23.52
$25.77
52주 변동 폭
$12.72
$29.25
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-410-3120
주소
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
23.60 | 5.09B | 0 | -464.20M | -423.09M | -2.6823 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.59 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.12 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.77 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.80 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.29 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant shares climb 7% as fiscal Q3 loss comes in better than expected - MSN
Immunovant, Inc. $IMVT is Alpine Global Management LLC's 3rd Largest Position - MarketBeat
Immunovant, Inc. $IMVT Shares Purchased by Granahan Investment Management LLC - MarketBeat
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? - AOL.com
HighVista Strategies LLC Grows Position in Immunovant, Inc. $IMVT - MarketBeat
Truist Securities Initiates Coverage of Immunovant (IMVT) with Hold Recommendation - MSN
Prosight Management LP Has $11.26 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immunovant stock surges 17% in 3 months: What's driving it? - MSN
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish - The Motley Fool
Immunovant, Inc. (IMVT) analysts raise price targets following Q3 earnings update - MSN
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN
The Technical Signals Behind (IMVT) That Institutions Follow - Stock Traders Daily
UBS Downgrades Immunovant (IMVT) - MSN
Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView
Immunovant Stock Pre-Market (+8.1%) : Key Analyst Upgrade Cites Pipeline Confidence - Trefis
Vanguard Group Inc. Has $110.05 Million Holdings in Immunovant, Inc. $IMVT - MarketBeat
TD Asset Management Inc Sells 56,752 Shares of Immunovant, Inc. $IMVT - MarketBeat
Citigroup Inc. Sells 75,860 Shares of Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update - Bitget
How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones - simplywall.st
Immunovant, Inc. (IMVT) Stock Analysis: A Compelling 48.2% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Immunovant (IMVT) COO executes 3,238-share sell-to-cover tax transaction - Stock Titan
Immunovant stock hits 52-week high at 28.32 USD By Investing.com - Investing.com Australia
Immunovant (NASDAQ:IMVT) Sets New 52-Week HighHere's What Happened - MarketBeat
Immunovant stock hits 52-week high at 28.32 USD - Investing.com
Precision Trading with Immunovant Inc. (IMVT) Risk Zones - Stock Traders Daily
Immunovant, Inc. (IMVT) Stock Analysis: Unpacking A 51% Potential Upside - DirectorsTalk Interviews
IMVT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - AOL.com
Assessing Immunovant (IMVT) Valuation As Shares Deliver A 25% One Year Return - Yahoo Finance
What are Immunovant Inc.’s earnings expectationsOil Prices & Risk Managed Investment Strategies - mfd.ru
Aberdeen Group plc Has $15.83 Million Stock Position in Immunovant, Inc. $IMVT - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Immunovant Inc. stock recover faster than marketTrade Analysis Report & Stepwise Swing Trade Plans - mfd.ru
What are analysts’ price targets for Immunovant Inc.Quarterly Trade Report & Capital Efficient Trading Techniques - mfd.ru
Technical Reactions to IMVT Trends in Macro Strategies - Stock Traders Daily
Why hedge funds are buying Immunovant Inc. stockMarket Trend Summary & Real-Time Volume Spike Alerts - mfd.ru
FY2026 EPS Forecast for Immunovant Increased by Analyst - MarketBeat
FY2030 EPS Estimates for Immunovant Raised by HC Wainwright - MarketBeat
Is now the right time to enter Immunovant Inc.Weekly Gains Report & Trade Opportunity Analysis Reports - mfd.ru
Immunovant (IMVT) Gets a Buy from Oppenheimer - The Globe and Mail
Immunovant (NASDAQ:IMVT) Given Buy Rating at HC Wainwright - MarketBeat
Immunovant stock hits all-time high at 27.87 USD By Investing.com - Investing.com Australia
Immunovant Rides Brepocitinib Momentum Into 2026 - TipRanks
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Finviz
Immunovant stock hits all-time high at 27.87 USD - Investing.com
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.69%
자본화:
|
볼륨(24시간):